Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc ...

Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...

ARK Invest's 13F portfolio value increased by ~10% to ~$12B this quarter. Check out the top holdings and new stakes of the ...

It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data ...

Saudi Arabia is leading the way in transforming cancer care with the establishment of the Oncology Center of Excellence, underscoring the Kingdom’s commitment to patient-centric, world-class oncology ...